Patents by Inventor Wen-Chun HUNG

Wen-Chun HUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CXCR2 Antibodies and Uses Thereof
    Publication number: 20240166756
    Abstract: Anti-CXCR2 antibodies that recognize CXCR2 and inhibit the activity of CXCR2, and the use of the anti-CXCR2 antibodies in the treatment of pancreatic cancer and leukemia.
    Type: Application
    Filed: April 25, 2022
    Publication date: May 23, 2024
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Li-Tzong Chen, Wen-Chun Hung, Ko-Jiunn Liu
  • Dual-function antibodies targeting VEGFR2 and VEGFR3
    Patent number: 11623960
    Abstract: An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 11, 2023
    Assignee: National Health Research Institutes
    Inventors: Neng-yao Shih, Ko-jiunn Liu, Li-tzong Chen, Wen-chun Hung, Yun-chang Chen, Kuan-chung Hsiao, San-tai Shen
  • DUAL-FUNCTION ANTIBODIES TARGETING VEGFR2 AND VEGFR3
    Publication number: 20210032353
    Abstract: An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Neng-yao Shih, Ko-jiunn Liu, Li-tzong Chen, Wen-chun Hung, Yun-chang Chen, Kuan-chung Hsiao, Sa-tai Shen
  • Sialyltransferase inhibitors and uses thereof
    Patent number: 10889611
    Abstract: Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 12, 2021
    Assignee: Academia Sinica
    Inventors: Wen-Shan Li, Wen-Chun Hung, Chia-Ning Shen
  • SIALYLTRANSFERASE INHIBITORS AND USES THEREOF
    Publication number: 20180244713
    Abstract: Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 30, 2018
    Inventors: Wen-Shan LI, Wen-Chun HUNG, Chia-Ning SHEN